Wiesel P H, Norton C, Brazzelli M
Division de Gastroenterologie & Hepatologie CHUV/pmu, PMU, 19 Rue Cesar-Roux, Lausanne, Switzerland.
Cochrane Database Syst Rev. 2001(4):CD002115. doi: 10.1002/14651858.CD002115.
People with neurological disease have a much higher risk of both faecal incontinence and constipation than the general population. There is often a fine dividing line between the two conditions, with any management intended to ameliorate, one risking precipitating the other. Bowel problems are observed to be the cause of much anxiety and may reduce quality of life in these people. Current bowel management is largely empirical with a limited research base.
To determine the effects of management strategies for faecal incontinence and constipation in people with neurological diseases affecting the central nervous system.
We searched the Cochrane Incontinence Group Trials Register, the Cochrane Controlled Trials Register, MEDLINE, EMBASE and all reference lists of relevant articles. Date of the most recent searches: May 2000.
All randomised or quasi-randomised trials evaluating any types of conservative, or surgical measure for the management of faecal incontinence and constipation in people with neurological diseases were selected. Specific therapies for the treatment of neurological diseases that indirectly affect bowel dysfunction have also been considered.
All three reviewers assessed the methodological quality of eligible trials and two reviewers independently extracted data from included trials using a range of pre-specified outcome measures.
Only seven trials were identified by the search strategy and all were small and of poor quality. Oral medications for constipation were the subject of four trials. Cisapride does not seem to have clinically useful effects in people with spinal cord injuries (two trials). Psyllium was associated with increased stool frequency in people with Parkinson's disease but not altered colonic transit time (one trial). Some rectal preparations to initiate defecation produced faster results than others (one trial). Different time schedules for administration of rectal medication may produce different bowel responses (one trial). Mechanical evacuation may be more effective than oral or rectal medication (one trial). The clinical significance of any of these results is difficult to interpret.
REVIEWER'S CONCLUSIONS: It is not possible to draw any recommendation for bowel care in people with neurological diseases from the trials included in this review. Bowel management for these people must remain empirical until well-designed controlled trials with adequate numbers and clinically relevant outcome measures become available.
与普通人群相比,神经疾病患者发生大便失禁和便秘的风险要高得多。这两种情况之间往往界限很细微,任何旨在改善其中一种情况的治疗方法,都有引发另一种情况的风险。据观察,肠道问题会导致这些患者产生诸多焦虑情绪,并可能降低其生活质量。目前的肠道管理方法大多基于经验,相关研究基础有限。
确定针对影响中枢神经系统的神经疾病患者大便失禁和便秘的管理策略的效果。
我们检索了Cochrane尿失禁组试验注册库、Cochrane对照试验注册库、MEDLINE、EMBASE以及所有相关文章的参考文献列表。最近一次检索日期为2000年5月。
所有评估针对神经疾病患者大便失禁和便秘的任何类型保守或手术治疗措施的随机或半随机试验均被纳入。还考虑了用于治疗间接影响肠道功能障碍的神经疾病的特定疗法。
三位综述作者评估了符合条件的试验的方法学质量,两位综述作者使用一系列预先设定的结局指标,独立从纳入试验中提取数据。
检索策略仅识别出7项试验,所有试验规模均较小且质量较差。有4项试验以治疗便秘的口服药物为研究对象。西沙必利似乎对脊髓损伤患者没有临床有用的效果(2项试验)。在帕金森病患者中,车前草与大便频率增加有关,但未改变结肠转运时间(1项试验)。一些用于启动排便的直肠制剂比其他制剂起效更快(1项试验)。直肠给药的不同时间安排可能会产生不同的肠道反应(1项试验)。机械排便可能比口服或直肠给药更有效(1项试验)。这些结果中任何一项的临床意义都难以解读。
从本综述纳入的试验中,无法得出针对神经疾病患者肠道护理的任何建议。在有足够数量且具有临床相关结局指标的精心设计的对照试验出现之前,这些患者的肠道管理仍必须基于经验。